7:22
Drug discovery and development process
Novartis
Overview
This video outlines the extensive journey of drug discovery and development, emphasizing a patient-centric approach. It details the process from identifying disease targets, discovering and refining potential drug compounds, through rigorous preclinical and multi-phase clinical trials. The summary highlights the significant time, cost, and low success rates involved, while also touching upon the ethical considerations of animal testing and the regulatory hurdles before a drug can reach patients and undergo post-market surveillance.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- The primary goal is to identify biological targets, often proteins, that are crucial to a disease's mechanism.
- Understanding cellular networks and pathways is increasingly important for selecting the most effective targets.
- High-throughput screening and computer-aided design are used to find compounds that interact with these targets.
- Promising compounds, or 'hits,' are then refined into drug candidates based on their potential to modulate the target and improve safety/efficacy.
Identifying the right target and initial compound is the foundational step that determines the potential success of any future medicine.
Novartis focuses on understanding cellular networks of proteins or pathways to better identify appropriate drug targets.
- Drug candidates undergo extensive preclinical testing to ensure safety and assess pharmacokinetic properties (how the body absorbs, distributes, metabolizes, and excretes the drug).
- Animal studies are critical for understanding complex disease mechanisms and are often required by regulatory bodies before human testing.
- While animal use is minimized and conducted to high ethical standards, it remains a necessary step in ensuring drug safety.
This stage is crucial for minimizing risks to human participants in later clinical trials and satisfying regulatory requirements.
Animals are used in studies because complex disease mechanisms can often only be understood through their use, and governments require it before human testing.
- Phase 1 trials test the drug's safety and pharmacokinetics in a small group of healthy volunteers.
- Phase 2 trials evaluate the drug's efficacy and determine the optimal dosage in a larger group of patients with the target disease, while also monitoring safety and side effects.
- Proof of Concept (POC) trials are often conducted as a mix of Phase 1 and 2 to quickly assess if the drug impacts the target or disease as intended.
- Phase 3 trials involve thousands of patients to confirm effectiveness, monitor side effects, compare the drug to existing treatments, and gather comprehensive safety data for regulatory submission.
These phased trials systematically gather evidence on a drug's safety and effectiveness, building confidence for regulatory approval and patient use.
In Phase 2, the drug is given to 100-250 patients with the disease to evaluate its efficacy and find the best dose.
- A comprehensive registration dossier, containing all efficacy and safety data from clinical trials, is submitted to health authorities for approval.
- This dossier is adapted for different regions to meet specific country requirements, a critical step for global patient access.
- After approval and launch, ongoing drug safety monitoring (pharmacovigilance) is mandatory, including reporting adverse events and providing updates.
- Phase 4 trials may be conducted post-launch to gather additional data on long-term efficacy, safety, benefits, and risks in real-world settings.
Regulatory approval ensures that only safe and effective drugs reach the market, and post-market surveillance continues to monitor their performance and safety in the broader patient population.
Data from all clinical trials are compiled into a document called a registration dossier, which is submitted to health authorities for approval.
Key takeaways
- Drug development is a lengthy, costly, and high-risk process with a very low success rate from initial discovery to market approval.
- A deep understanding of disease mechanisms at the cellular and pathway level is essential for identifying effective drug targets.
- Rigorous testing in preclinical and multiple phases of clinical trials is necessary to ensure a drug's safety and efficacy before it can be approved for patient use.
- Ethical considerations, particularly regarding animal testing, are carefully managed throughout the development process.
- Regulatory bodies play a vital role in approving drugs based on submitted data, and ongoing monitoring ensures continued safety after a drug is on the market.
- The ultimate goal of drug discovery and development is to improve patient quality of life by providing effective and safe treatments for unmet medical needs.
Key terms
Drug DiscoveryDrug DevelopmentTarget IdentificationProteinsPathwaysHigh-throughput screeningDrug CandidatePreclinical StagePharmacokineticsClinical TrialsEfficacyPharmacovigilanceRegistration Dossier
Test your understanding
- What are the primary challenges in identifying effective drug targets?
- Why are animal studies still considered necessary in the drug development process, despite ethical considerations?
- How does the focus of Phase 1, Phase 2, and Phase 3 clinical trials differ in evaluating a new drug?
- What is the purpose of a registration dossier, and why is it crucial for bringing a drug to market globally?
- What is pharmacovigilance, and why is it important even after a drug has been approved and launched?